A5057434912- Myasthenia Gravis and Thymoma
- Peripheral Neuropathies and Disorders
- Neurological disorders and treatments
- Botulinum Toxin and Related Neurological Disorders
- Parkinson's Disease Mechanisms and Treatments
- Parkinson's Disease and Spinal Disorders
- Autoimmune Neurological Disorders and Treatments
- Meningioma and schwannoma management
- Hereditary Neurological Disorders
- Ophthalmology and Eye Disorders
- Salivary Gland Tumors Diagnosis and Treatment
- Thyroid and Parathyroid Surgery
- Antifungal resistance and susceptibility
- Amyotrophic Lateral Sclerosis Research
- Vascular Malformations and Hemangiomas
- Neurology and Historical Studies
- Peripheral Nerve Disorders
- Neurogenetic and Muscular Disorders Research
- History of Medicine Studies
- Retinoids in leukemia and cellular processes
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Cardiac Arrest and Resuscitation
- Salivary Gland Disorders and Functions
- Genetic Neurodegenerative Diseases
- Cholinesterase and Neurodegenerative Diseases
Antwerp University Hospital
2008-2023
University of Antwerp
1982-2023
Universitair Ziekenhuis Leuven
2017
Ghent University Hospital
2017
VIB-UAntwerp Center for Molecular Neurology
2017
AZ Sint-Jan
2017
Neurology, Inc
2004
Royal Library of Belgium
1987
Province of Antwerp
1987
Ipse de Bruggen
1987
<h3>Objective</h3> To evaluate whether eculizumab helps patients with anti–acetylcholine receptor–positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status minimal manifestations (MM), we assessed patients9 throughout REGAIN (Safety and Efficacy Eculizumab in AChR+ Refractory Generalized Gravis) its open-label extension. <h3>Methods</h3> Patients who completed randomized controlled trial continued into...
Objective: To prospectively evaluate quality of life (QoL) evolution after robotic-assisted thoracoscopic or open anterior mediastinal tumour resection with the European Organisation for Research and Treatment Cancer (EORTC) QoL Questionnaire-C30 lung cancer-specific module, LC-13. Methods: From January 2004 to December 2008, was recorded in all patients undergoing surgery tumours. A total 14 underwent using da Vinci robotic system (Intuitive Surgical, Inc., Mountain View, CA, USA), 22...
To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-positive, refractory, generalized myasthenia gravis (MG) using Quality Life Neurological Disorders (Neuro-QOL) Fatigue subscale, and to correlations between improvements Neuro-QOL other clinical endpoints.Neuro-QOL Fatigue, MG Activities Daily Living (MG-ADL), Quantitative (QMG), 15-item (MG-QOL15) scales were administered during phase 3, randomized, placebo-controlled REGAIN study...
We evaluated the genetic impact of amyotrophic lateral sclerosis (ALS) risk gene never in mitosis a–related kinase 1 (NEK1) a Belgian cohort 278 patients with ALS (n = 245) or frontotemporal dementia (ALS-FTD, n 33) and 609 control individuals. identified 2 carrying loss-of-function (LOF) mutation, p.Leu854Tyrfs*2 p.Tyr871Valfs*17, that was absent group. A third LOF variant p.Ser1036* present sibs familial but also an unrelated person. Missense variants were common both (3.6%) controls...
<h3>Objective</h3> To study the frequency and distribution of mutations in<i>SPG3A</i>in a large cohort patients with hereditary spastic paraplegia. <h3>Design</h3> We screened 182 families isolated cases pure or complex paraplegia phenotypes, which were negative for in<i>SPG4</i>. <h3>Results</h3> In 12 probands (6.6%), we identified different<i>SPG3A</i>mutations (11 missense 1 insertion/frameshift) 7 novel 3 de novo. found incomplete penetrance in family (G482V). most...
Stimulated single-fiber electromyography (SSFEMG) is a valuable diagnostic tool in cases of myasthenia gravis with limited disease. From 1990 to 2008 SSFEMG the orbicularis oculi muscle (OO) was performed cohort 456 patients referred clinical suspicion (MG) and exclusively ocular symptoms. A diagnosis MG made on grounds 103 patients. In this patient cohort, specificity for 97%, sensitivity 80%. normal had benign course. This study confirms high when it suspected have MG. such patients, OO predicts
The terminal complement inhibitor eculizumab was shown to improve myasthenia gravis-related symptoms in the 26-week, phase 3, randomized, double-blind, placebo-controlled REGAIN study (NCT01997229). In this 52-week sub-analysis of open-label extension (NCT02301624), eculizumab's efficacy and safety were assessed 11 Japanese 88 Caucasian patients with anti-acetylcholine receptor antibody-positive refractory generalized gravis. For who had received placebo during REGAIN, treatment resulted...
Abstract Objectives Patients with idiopathic adult‐onset cervical dystonia ( CD ) experience an abnormal head posture and involuntary muscle contractions. Although the exact areas affected in central nervous system remain uncertain, impaired functions systems stabilizing neck are apparent such as somatosensory sensorimotor integration systems. The aim of study is to investigate control dysfunction patients . Material Methods Cervical was assessed by a repositioning task 24 70 asymptomatic...
Cervical Dystonia (CD) is a rare movement disorder characterized by an abnormal head position. This cross-sectional study describes the health status and severity of disability using internationally agreed language applying International Classification Functioning, Disability Health (ICF). Two disease-specific rating scales were administered to 30 patients with CD. By linking individual answers ICF model, frequency reported impairments restrictions estimated count-based method. Results...
Introduction: Thirty to fifty percent of thymoma patients develop myasthenia gravis (MG). In 1.5–28% cases, MG appears many years after removal a thymoma.Patients and methods: We present case report 72-year-old female who presented with four months total thymectomy.Results: A patient presents thymectomy. Imaging revealed PET-positive nodule anterior the superior vena cava. By median sternotomy, was removed at our hospital. Pathology confirmed recurrent B2/B3 R0 resection. No adjuvant therapy...